Form 4 Filing for Mathew Aby J. - BIOLIFE SOLUTIONS INC

On October 6, 2026, Mathew Aby J., EVP & Chief Scientific Officer of BIOLIFE SOLUTIONS INC, reported several transactions involving the company's common stock. These transactions include the acquisition of 45,838 shares and 40,192 shares, both at a price of $0.00, noted as restricted stock grants that vested prior to a merger. Additionally, 70,000 shares were disposed of at a price of $38.61, and 404,608 shares were disposed of with a price noted in a footnote related to a merger. These transactions resulted in a post-transaction ownership of 0 shares for Mathew Aby J. The merger involved Bravo Merger Sub I, Inc. and Repligen Corporation, where each share of BioLife Solutions common stock was converted into $11.25 in cash and 0.1442 shares of Repligen common stock.